The BioHealth Capital Region (BHCR) continues to thrive and currently occupies the fourth spot in the most recent Genetic Engineering & Biotechnology (GEN) top ten U.S. biohealth cluster rankings. More importantly, the collaborative efforts across industry, academia, government and nonprofits within the BHCR have generated powerful momentum that is now producing tangible results: The region has moved up two spots in GEN’s rankings in the last five years.
BHI is looking to add to our team! We have a new opening for an Analyst. Our analysts assist in the evaluation of early-stage technologies and provide strategic planning and operational support for start-up companies. They support the BHI organization by strategically managing and providing information, intelligence and insights that drive critical business decisions. For details on this exciting role and information on how to apply click here.
Three move-in ready laboratory/office modules; each approximately 1,200 RSF with communal services and amenities designed to facilitate collaboration.
Fully fit out laboratory space
Office space includes one furnished office and two workstations
Communal space includes reception/lobby area, pantry, conference rooms, IT closet, autoclave, glass wash, and ice maker
BioHealth Innovation will provide their Startup and Entrepreneur-in-Residence programs and various supporting services to guide and facilitate the growth of early-stage companies
FitLab, Alexandria’s state-of-the-art fitness center, is located in close proximity
Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School Neurosurgeon-in-Chief and Chairman, Department of Neurosurgery, Brigham and Women’s Hospital to its scientific advisory board. ITI is currently applying its investigational UNITE™ platform in immuno-oncology, particularly for virally driven brain cancers, and Dr. Chiocca’s extensive expertise in this field will be instrumental to these efforts.
QIAGEN N.V. has announced that it has decided to integrate its global sales resources into its Business Areas (Life Sciences, Molecular Diagnostics and Bioinformatics). This transition is expected to allow the Business Areas to oversee the full value chain from innovation to commercialization, which is expected to further increase focus and agility. QIAGEN plans to provide an update during the fourth quarter of 2019.
With product candidates acquired from AstraZeneca (AZN) and MedImmune, Viela Bio (VIE) is clinical-stage biotechnology to be followed carefully. Besides, at Phase 3 of development, the company could deliver positive results in 2020, which may make the share price run. After the IPO, we expect Viela to have an enterprise value between $180 and $310 million. With that, in our opinion, savvy individuals will try to acquire shares at an enterprise value of $200 million.
United Therapeutics Corporation (UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020. Trevyent is a post-phase III development-stage drug-device combination product that combines two-day, single use, disposable PatchPump® technology with treprostinil, for the subcutaneous treatment of PAH.
In the world of drug discovery and development, there is increasing pressure to get novel products to market faster, cheaper and ahead of the competition. This is exactly what Insilico Medicine is helping leading pharmaceutical companies to achieve through their artificial intelligence technology for drug discovery.
RegenxBio Inc. just locked in another deal — this one with a company working to treat eye diseases.
The Rockville biotech has reached a licensing agreement with Alpharetta, Georgia-based Clearside Biomedical Inc. (NASDAQ: CLSD) for rights to its platform to treat several eye diseases including wet age-related macular degeneration and diabetic retinopathy. RegenxBio (NASDAQ: RGNX) plans to evaluate one of its own gene therapy programs, called RGX-314, using Clearside’s in-office injection as an alternative to surgery.
Baltimore-based Capsulomics won the top award in Utah last month at a pitch competition that was part of a boot camp for early-stage companies founded by military members, veterans and military spouses.
The Maryland Momentum Fund has been successful in its first couple of years but needs to do a better job of marketing itself to all of the University System of Maryland’s institutions, the fund’s director told the system’s Board of Regents Thursday. The fund, which the system uses to invest in startups related to system institutions, has …
“I think most of you know how deeply I care for this city and its people, how much I love being part of a place with so much grit, and grace, and potential,” University of Maryland, Baltimore (UMB) President Jay A. Perman, MD, told several hundred members of the Downtown Partnership of Baltimore (DPOB) at the group’s annual meeting Sept. 12. “I can’t imagine a higher honor than being in a position to help Baltimore reach that potential, to help it become what we know it can be.”
Lockheed Martin recently signed a $3 million charitable commitment to the University of Maryland A. James Clark School of Engineering. The three-year contribution will be used to fund work-related to vertical takeoff and landing research at the school’s rotorcraft lab, and high-speed flight experiments reaching up to Mach 8, or 6,000 mph.
With nothing more than a passing glance, the U.S. Food & Drug Administration’s (FDA) approval of Roche Holdings’ (OTC:RHHBY) cancer drug entrectinib last month was a run-of-the-mill announcement. In fact, it was almost boilerplate in its tone and feel.
University of Maryland researchers have discovered that seemingly identical cells can use different protein molecules to carry out the same function in an important cellular process. The scientists named this newly discovered variability “functional mosaicism,” and it has significant implications for the development of therapeutic treatments, which are often designed to target a specific molecule, or a gene that produces a specific molecule.
A small clinical study in California has suggested for the first time that it might be possible to reverse the body’s epigenetic clock, which measures a person’s biological age.
For one year, nine healthy volunteers took a cocktail of three common drugs — growth hormone and two diabetes medications — and on average shed 2.5 years of their biological ages, measured by analysing marks on a person’s genomes. The participants’ immune systems also showed signs of rejuvenation.
Venture funding for digital health companies reached an all-time high in the first half of 2019, totaling $5.1 billion across 318 deals, according to a recent report.
